



ISSN: 0975-833X

Available online at <http://www.journalcra.com>

International Journal of Current Research
Vol. 10, Issue, 10, pp.74464-74469, October, 2018

DOI: <https://doi.org/10.24941/ijcr.32728.10.2018>

INTERNATIONAL JOURNAL
OF CURRENT RESEARCH

RESEARCH ARTICLE

MICROBIOLOGICAL QUALITY ANALYSIS OF ORAL LIQUID ANTIBIOTICS AND ASSESSMENT OF THE ANTIMICROBIAL EFFICACY

1,*Md. Tanjidul Hasan, 2Dr. Tarana Tabashum, 3S.M. Yasir Arafat, 4Nilufar Banu and 5Md. Zahidul Islam

¹Scientific Officer, Universal Medical College and Hospital, Dhaka, Bangladesh.

²Assistant Professor, MD Pathology (BSMMU), East-West Medical College, Bangladesh

³MD Resident, Department of Psychiatry, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

⁴Instructor (Lab), Department of Biochemistry, Universal Medical College and Hospital, Dhaka, Bangladesh

⁵Junior Consultant, Department of Biochemistry, Bangladesh Institute of Health Sciences Hospital (A sister concern of BIRDEM), Dhaka, Bangladesh

ARTICLE INFO

Article History:

Received 20th July, 2018

Received in revised form

15th August, 2018

Accepted 28th September, 2018

Published online 31st October, 2018

Key words:

Efficacy of Flucoxacillin,
Antibiotic Quality,
Oral liquid Suspension Efficacy.

ABSTRACT

The current study was designed to demonstrate the microbiological quality of oral liquid antibiotics. The *in vitro* antibacterial potential of the antibiotics was checked. In this regard three samples of oral liquid suspension of Flucoxacillin collected from different drug stores of Dhaka city were tested. All the samples were found to be loaded with total viable bacteria and fungi in the average of 10⁴ cfu/ml and the bacterial and fungal load exceeded United States Pharmacopeia (USP) or British Pharmacopeia (BP) limit ($\leq 10^2$ cfu/ml for bacteria and 10 cfu/ml for fungi). Pathogenic bacteria were also encountered among which *Pseudomonas* spp. was predominant as they found in all samples. *Escherichia coli* and *Staphylococcus* spp. were found in majority of the samples. All the samples of antibiotic exhibited substantial killing effect on *E. coli*, *Staphylococcus* spp. and fungi. Flucoxacillin samples had effect on them. *E. coli*, *Klebsiella* spp., *Staphylococcus* spp. and fungi. Flucoxacillin had the elevated antimicrobial effect on *Staphylococcus* spp.

Copyright © 2018, Md. Tanjidul Hasan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Md. Tanjidul Hasan, Dr. Tarana Tabashum, S.M. Yasir Arafat, Nilufar Banu and Md. Zahidul Islam. 2018. "Microbiological quality analysis of oral liquid antibiotics and assessment of the antimicrobial efficacy", *International Journal of Current Research*, 10, (10), 74464-74469.

INTRODUCTION

Bacterial infections are among the important infectious diseases. Hence, over 5 decades of extensive researches have been launched for achieving new antimicrobial medicines isolated from different sources for combating bacterial infections that once ravaged humankind (Moat et al., 2002, Kamat et al., 2006, Lovine et al., 2008). Different antibiotics exercise their inhibitory activity on different pathogenic organisms. Despite progress in development of antibacterial agents, there are still special needs to find new antibacterial agents due to development of multidrug resistant bacteria (Sayeed et al., 2014). The increasing phenomenon of acquisition of resistance among microorganisms to antimicrobial drugs is attributed to the indiscriminate and

improper use of current antimicrobial drugs (Usha et al., 2010). Today, clinically important bacteria are characterized not only by single drug resistance, but also by multiple antibiotic resistance - the legacy of past decades of antimicrobial use and misuse. Drug resistance presents an ever increasing global health threat that involves all major microbial pathogens and antimicrobial drugs. Antibiotics that work today may not work tomorrow. It is essential to investigate newer drugs to which there is lesser resistance (Levy, 2002). Beside the resistance concern, presence of microorganism in oral suspension liquid (syrup) antibiotic preparation is a great public health concern globally (Cundell 2005a, 2005b, Prescott et al., 2005). Contaminations in pharmaceutical preparations with microorganisms irrespective of being pathogenic and non-pathogenic can bring about changes in their physical characteristics, breaking of emulsion, fermentation appearance of turbidity or deposit and producing off odors and color changes (Hugo and Russel, 1988, Squadrito et al., 1998, Cabiscol et al., 2000, Schutterm et al., 2000).

*Corresponding author: Md. Tanjidul Hasan,
Scientific Officer, Universal Medical College and Hospital.

Moreover, paediatric oral liquid drug formulations may introduce pathogenic microorganisms to infants. Further, these pathogenic organisms may be highly detrimental for immunocompromised infants. Therefore, microbiological quality of such oral liquid medicines is a very important factor for the above mentioned patients (Hossain *et al.*, 2009, Sykes *et al.*, 1971). By considering the facts discussed above, the present study was undertaken to investigate the microbiological attributes of commonly available antibiotics Flucoxacillin.

MATERIALS AND METHODS

Sample Collection and processing: Liquid suspension of antibiotics such Flucoxacillin of the three different companies (Phylophen –Square, Flux- Opsonin, Revistar- Biopharma) were collected from different drug store of Dhaka City. A total of 250 mg suspension powder of both types of antibiotic were mixed with 10 ml autoclaved distilled water. All the suspensions were then diluted up to 10^{-2} following standard guidelines (Choudhury *et al.* 2015; Cappuccino and Sherman 1996; Acharjee *et al.* 2013; Ahmed *et al.* 2014).

Microbiological Analysis

Estimation of Total Viable Bacteria and Fungi: For the enumeration of total viable bacteria (TVB) and the total fungal load, 0.1 ml of each sample from the dilutions 10^{-1} and 10^{-2} was introduced onto the nutrient agar (NA) plate (Hi media laboratories Pvt. Ltd Mumbai, India) and Sabouraud's dextrose agar (SDA) plates (Bhiwadi- 301019, Rajasthan India), respectively, by means of spread plate technique. Plates were incubated at 37 °C for 24 hours and at 25 °C for 48 hours for total viable bacteria and fungi, respectively (Sharmin *et al.*, 2015; Cappuccino and Sherman, 1996; Acharjee *et al.*, 2013; Acharjee *et al.*, 2014; Ahmed *et al.*, 2014).

Estimation of *Escherichia coli*, *Klebsiella spp.*, *Staphylococcus spp.* and *Pseudomonas spp.*, *Bacillus spp.*: From the dilutions 10^{-1} and 10^{-2} , 0.1 ml of each sample was spread onto the Mac Conkey agar plate (Hi media laboratories Pvt. Ltd Mumbai, India) for the enumeration of coliforms (especially, *Escherichia coli* and *Klebsiella spp.*), respectively. Plates were incubated for 24 hours at 37 °C for coliforms, correspondingly. Likewise, *Staphylococcus spp.*, *Pseudomonas spp.*, *Bacillus spp.* were isolated onto Mannitol Salt Agar (MSA) plate (Hi media laboratories Pvt. Ltd Mumbai, India) and *Pseudomonas* agar plate, Starch agar (Hi media laboratories Pvt. Ltd Mumbai, India) respectively by adding 0.1 ml of diluted sample each, and all the plates were then incubated at 37 °C for 24 hours (Sharmin *et al.*, 2015; Cappuccino and Sherman, 1996; Acharjee *et al.*, 2013; Acharjee *et al.*, 2014; Ahmed *et al.*, 2014).

Biochemical identification of the isolates: All the isolates were biochemically examined following standard procedures as described earlier (Sharmin *et al.*, 2015; Cappuccino and Sherman, 1996; Acharjee *et al.*, 2013; Acharjee *et al.*, 2014; Ahmed *et al.*, 2014). Biochemical testing was performed for selection specific microorganisms such as Triple Sugar Iron (TSI) Slants (Hi media laboratories Pvt. Ltd Mumbai, India), Methyl-Red (MR), Voges-Proskauer (VP), Motility Indole Urease (MIU) semisolid medium (Hi media laboratories Pvt.

Ltd Mumbai, India), Citrate Utilization Slants (Becton Dickinson and company, France), Catalase test and Oxidase test.

Assay of determining anti-bacterial properties of samples through agar well diffusion method: Agar well diffusion method was performed to determine the antimicrobial activity of the Antibiotic samples (Jagessar *et al.*, 2008). Individual bacterial pathogens (*Pseudomonas spp.*, *Klebsiella spp.*, *E.coli*, *Staphylococcus aureus* and *Bacillus spp.*) were spread properly over Muller Hinton Agar (Oxoid, Ltd Hampshire England) plates using sterile cotton swabs (Ahmed *et al.*, 2013). Wells were made in MHA by cork borer. Each of the antibiotics were used directly on MHA, separately. Sample solutions were added in wells along with a positive control (Gentamycin disc: 10µg) and a negative control (Normal Saline). The presence of antimicrobial activity was determined by the production of a clear zone around the wells and the diameters of these zones were then measured. (Hussain *et al.*, 2010).

RESULTS AND DISCUSSIONS

Microbiological quality of antibiotic samples: Many factors can increase microbial contamination during consumption includes improper storage conditions, unhygienic handling of the product, not following aseptic procedures when opening of the bottles and reconstituting. Air, water, reconstituting equipment's, reconstituting personnel and the consumer can be taken as the major sources of microbial contamination of oral liquid drug formulations. There have been an increasing number of reports of infections due to above mentioned reasons (Adeshina *et al.*, 2009). In present study microbial contaminations were evident. All the samples were found to harbor viable bacteria and fungi in average of 10^4 cfu/ml irrespective of the type of antibiotic tested (Table I). *Pseudomonas spp.* was predominantly present in all the samples in a range of 10^2 to 10^4 cfu/ml. However *E.coli* and *Bacillus spp.* were found in six samples in a range of 10^2 to 10^3 cfu/ml; whereas, *Staphylococcus spp.* were encountered in five samples. Three samples found to harbor *Klebsiella spp.* (Table II). Presence of pathogenic bacteria was confirmed by biochemical identification test (Table II). According to USP or BP, the finished products of the oral aqueous preparation should not go over the limit of 10^2 cfu/ml for total aerobic microbial count and 10 cfu/ml for total yeast mold count. *E. coli* must be absent from both categories of oral preparations (Noor *et al.*, 2015). The microbial load found in our study clearly exceeded the USP or BP recommended microbial limit. Presence of microorganisms in oral liquid was also previously evident in different formulation of oral liquid drugs in Bangladesh (Noor *et al.*, 2015, Khanom *et al.*, 2013, Urmi and Noor, 2014).

Antimicrobial activity of antibiotics: Antimicrobial activities of non-antibiotic drugs have been demonstrated in several Studies previously (Noor *et al.*, 2015, Akon *et al.*, 2015, Quaiyum *et al.*, 2014, Sharmin *et al.*, 2014, Sultana *et al.* 2014). Our current study aimed to investigate the antimicrobial effect of locally available oral suspension of antibiotics. All the samples of both Flucoxacillin were effective in killing of *E. Coli*, *Staphylococcus spp.*, *Klebsiella spp.* and fungi. as large zone of inhibition representing sensitivity was found (Table III). *Bacillus spp.* were found to acquire resistance against all the samples of Flucoxacillin.

Table 1. Microbial proliferation in Fluoxicillin

Antibiotic	Micobial load (cfu/ml)						
	TVB	TFC	<i>E. coli</i>	<i>Klebsiella spp.</i>	* <i>Bacillus spp.</i>	<i>Pseudomonas spp.</i>	<i>Staphylococcus spp.</i>
Fluoxicillin							
1	4.5×10 ⁴	8.0×10 ³	2.3×10 ³	2.3×10 ³	0	2.1×10 ³	0
2	1.3×10 ⁴	7.5×10 ³	1.2×10 ³	0	1.8×10 ²	1.7×10 ³	3.0×10 ³
3	1.6×10 ⁴	6.0×10 ³	9.0×10 ³	9.0×10 ³	1.2×10 ²	1.1×10 ⁴	2.5×10 ³

TVB= Total viable bacteria; TFC= Total fungal count

The experiments were in triplicates. Average count (cfu/ml or g) from all samples have been shown here.

*Bacterial load after enrichment (Prior to enrichment, the recovery was nil).

Vibrio spp. and *Shigella spp.* were absent in all samples.

USP or BP microbial limit: TVMC ≤10² cfu/ml; not more than 10 cfu/ml TYMC; *E. coli* should be absent.

Table 2. Biochemical identification of pathogenic isolates

Organisms	TSI				Motility	Indole	MR	VP	Citrate	Catalase	Oxidase
	Slant	Butt	Gas	H ₂ S							
<i>E. coli</i>	Y	Y	+	-	+	+	+	-	+	+	-
<i>Klebsiella spp.</i>	Y	Y	+	-	+	+	+	-	+	+	-
<i>Staphylococcus spp.</i>	Y	R	-	-	-	-	+	+	-	+	-
<i>Pseudomonas spp.</i>	R	R	-	-	-	-	-	-	-	+	+
<i>Bacillus spp.</i>	Y	R	-	-	+	-	-	+	+	+	-

Table 3. Antimicrobial activity of antibiotics against laboratory microbial isolates

Antibiotic	Zone of inhibition (mm) against test bacteria and fungus					
	<i>E. coli</i>	Fungi	<i>Klebsiella spp.</i>	<i>Bacillus spp.</i>	<i>Pseudomonas spp.</i>	<i>Staphylococcus spp.</i>
Fluoxicillin						
1	40mm (S)	19 mm (S)	23mm (S)	0mm (S)	8mm (R)	43mm (S)
2	42mm (S)	20 mm (S)	21mm (S)	0 mm (S)	0mm (R)	40mm (S)
3	38mm (S)	24mm (S)	18mm (S)	0 mm (S)	0mm (R)	42mm (S)

Conclusion

All the oral liquid antibiotic samples contained a significantly higher number of microorganisms including the pathogenic ones. The microbial load exceeded the USP or BP recommended microbial limit to an extent which accounts for high public health concern. Thus, the local pharmaceutical industries need to be more careful and attentive about following the safety rules and standard regulations in all stages of manufacturing, packaging and distribution of the products. The local stores should maintain the appropriate conditions for the storage of the pharmaceutical products. Presence of some resistant pathogenic isolates against the tested antibiotics was also of a major concern.

REFERENCES

- Abouzeed, Y. M., Baucheron, S. and Cloeckert, A. 2008. ramR mutations involved in efflux-mediated multidrug resistance in *Salmonella enterica* serovar Typhimurium. *Antimicrob. Agents Chemother.* 52, 2428–2434.
- Abraham, E. P. and Chain, E. 1988. An enzyme from bacteria able to destroy penicillin. 1940. *Rev. Infect. Dis.*, 10, 677–678.
- Acharjee M., Rahman F., Jahan F., Noor R. 2013. Bacterial proliferation in municipal water supplied in Mirpur locality of Dhaka city, Bangladesh. *Clean (Weinh)* 42(4): 434-441.
- Ahmad I., Aqil F. 2007. In vitro efficacy of bioactive extracts of 15 Medicinal plants against ESBL producing multi-drug-resistant enteric bacteria. *Microbiol. Res.*; 162: 264-275
- Alam SMS, Kalam MA, Munna S, Munshi SK, Noor R. 2014. Isolation of pathogenic microorganisms from burn patients admitted in Dhaka Medical College and Hospital and demonstration of their drug-resistance traits. *Asian Pac J Trop Dis*; 4(5): 402-407.
- Alekshun, M. N. and Levy, S. B. 1997. Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. *Antimicrob. Agents Chemother.* 41, 2067–2075.
- American Public Health Association. Standard methods for the examination of water and wastewater. Washington DC: American Public Health Association; 1998.
- Arullappan S, Zakaria Z, Basri DF. 2009 Preliminary screening of antibacterial activity using crude extracts of *Hibiscus rosa sinensis*. *Trop Life Sci Res*; 20(2): 109-118.
- Baroud, M. *et al.* 2013. Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli* isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases. *Int. J. Antimicrob. Agents* 41, 75–79
- Baucheron, S. *et al.* 2013. ramR mutations affecting fluoroquinolone susceptibility in epidemic multidrug-resistant *salmonella enterica* serovar kentucky ST198. *Front. Microbiol.* 4, 213.
- Baucheron, S. *et al.* 2014. Bile-mediated activation of the *acrAB* and *tolC* multidrug efflux genes occurs mainly through transcriptional derepression of *ramA* in *Salmonella enterica* serovar Typhimurium. *J. Antimicrob. Chemother.* 69, 2400–2406.
- Billal, D. S., Feng, J., Leprohon, P., Legare, D. and Ouellette, M. 2011. Whole genome analysis of linezolid resistance in *Streptococcus pneumoniae* reveals resistance and compensatory mutations. *BMC Genomics* 12, 512.
- Blahova J, Kralikova K, St Krcmery V. Antibiotic resistance. *Cas Lek Cesk.* 1999; 138, No. 11: 343–7.)

- Brinkhaus B., Linder M., Schuppan D., Hahn E. G. 2000. Chemical, Pharmacological and Clinical Profile of the East African medicinal Plant *Centella asiatica*. *Phytomedicine*, 7 (5): 427-448.
- Chanda S., Dudhata S., Kaneria M. 2010. Antioxidative and antibacterial effects of seeds and fruit rind of nutraceutical plants belonging to the family Fabaceae family. *Food and Function*, 1:308-315.
- Chanda S. and Rakholiya K. 2011. Combination therapy: Synergism between natural plant extracts and antibiotics against infectious diseases. *Microbiol Book Series*, 520-529.
- Chen, Y.H., Peng, C. F., Lu, P.L. Tsai, J.J. T.P. 2004. In vitro activities of antibiotic combinations against clinical isolates of *Pseudomonas aeruginosa*, *Kaohsiung J. Med. Sci.* 20 261-267.
- Cheok M H., Yang W., Pui C . H., Downing J R., Cheng C., Naeve C W. Relling M V. and Evans W E. 2003. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells, *Nat Genet*, 34 85.
- Cottarel G, Wierzbowski J. 2007. Combination drugs, an emerging option for antibacterial therapy. *Trends Biotechnol.* 25:547-555. <http://dx.doi.org/10.1016/j.tibtech.2007.09.004>.
- Cottell, J. L. et al. 2011. Complete sequence and molecular epidemiology of IncK epidemic plasmid encoding blaCTX-M-14. *Emerg. Infect. Dis.* 17, 645-652.
- Cottell, J. L., Webber, M. A. and Piddock, L. J 2012. Persistence of transferable extended-spectrum- β -lactamase resistance in the absence of antibiotic pressure. *Antimicrob. Agents Chemother.* 56, 4703-4706.
- Cunha BA. 2004. Therapeutic implications of antibacterial resistance in community-acquired respiratory tract infections in children. *Infection* 32:98-108. <http://dx.doi.org/10.1007/s15010-004-3065-5>.
- Das KK., Fatema KK., Nur IT., Noor R. 2013. Prevalence of microorganisms in commonly used cosmetics samples in Dhaka metropolis. *J Pharm Sci Innov.*, 2(6): 7-9.
- Dhanji, H. et al. 2011. Molecular epidemiology of fluoroquinolone-resistant ST131 *Escherichia coli* producing CTX-M extended-spectrum β -lactamases in nursing homes in Belfast, UK. *J. Antimicrob. Chemother.* 66, 297-303.
- Djeussi DE., Noumedem JAK., Seukey JA., Fankam AG., Voukeng IK., Tankeo SB., Nkuete AHL., Kuete V. 2013. Antibacterial activities of selected edible plants extracts against multidrug-resistant gram-negative bacteria. *Biomed central complementary and alternative medicine* 13, 164.
- Dolejska, M., Villa, L., Poirel, L., Nordmann, P. and Carattoli, A. 2013. Complete sequencing of an IncHI1 plasmid encoding the carbapenemase NDM-1, the ArmA 16S RNA methylase and a resistance nodulation cell division/multidrug efflux pump. *J. Antimicrob. Chemother.* 68, 34-39.
- Everett, M. J., Jin, Y. F., Ricci, V. and Piddock, L. J. 1996. Contributions of individual mechanisms to fluoroquinolone resistance in 36 *Escherichia coli* strains isolated from humans and animals. *Antimicrob. Agents Chemother.* 40, 2380-2386.
- Floyd, J. L., Smith, K. P., Kumar, S. H., Floyd, J. T. and Varela, M. F. 2010. LmrS is a multidrug efflux pump of the major facilitator superfamily from *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 54, 5406-5412.
- Forrest GN, Tamura K. 2010. Rifampin combination therapy for non-mycobacterial infections. *Clin. Microbiol. Rev.* 23:14-34. <http://dx.doi.org/10.1128/CMR.00034-09>.
- Fritsche, T. R., Castanheira, M., Miller, G. H., Jones, R. N. and Armstrong, E. S. 2008. Detection of methyltransferases conferring high-level resistance to aminoglycosides in Enterobacteriaceae from Europe, North America, and Latin America. *Antimicrob. Agents Chemother.* 52, 1843-1845.
- Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS (ed). 2010. The Sanford guide to antimicrobial therapy, 40th ed. Antimicrobial Therapy, Inc., Sperryville, VA.
- Habbal O, Hasson SS, El-Hag AH, Al-Mahrooqi Z, Al-Hashmi N, Al-Bimani Z, Al-Balushi MS, Al-Jabri AA. Antibacterial activity of *Lawsonia inermis* linn (Henna) against *Pseudomonas 14. aeruginosa*. *Asian Pacific Journal of Tropical Biomedicine.* 2011;1:173-176.
- Hand K. 2006. Tuberculosis: pharmacological management. *Hosp. Pharm.* 13:81-85.
- Haroun MF, Al-Kayali RS. 2016 Synergistic effect of *Thymbra spicata* L. extracts with antibiotics against multidrug-resistant *Staphylococcus aureus* and *Klebsiella pneumoniae* strains. *Iran J Basic Med Sci*; 19:1193-1200.
- Hidalgo, L. et al. 2013. Association of the novel aminoglycoside resistance determinant RmtF with NDM carbapenemase in Enterobacteriaceae isolated in India and the UK. *J. Antimicrob. Chemother.* 68, 1543-1550.
- Imming P, Sinning C H and Meyer A, Drugs, their targets and the nature and number of drug targets, *Drug Discov*, 5 (2006) 821.
- Johnson, A. P. and Woodford, N. 2013. Global spread of antibiotic resistance: the example of New Delhi metallo- β -lactamase (NDM)-mediated carbapenem resistance. *J. Med. Microbiol.* 62, 499-513.
- Kaatz, G. W., Thyagarajan, R. V. and Seo, S. M. 2005. Effect of promoter region mutations and mgrA overexpression on transcription of norA, which encodes a *Staphylococcus aureus* multidrug efflux transporter. *Antimicrob. Agents Chemother.* 49, 161-169.
- Kanchan Joshi and Preeti Chaturvedi; therapeutic efficiency of *Centella asiatica* (L.) Urb. an underutilized green leafy vegetable : an overview *Int., J. Pharm. Bio. Sci.*, 2013 Jan; 4(1): (P) 135 - 149
- Khan SA., Feroz F., Noor R. 2013. Study of extended spectrum β -lactamase producing bacteria from urinary tract infection in Dhaka city, Bangladesh. *Tzu. Chi. Med. J.*, 25(1): 39-42.
- Khanom S., Das KK., Banik S., Noor R. 2013. Microbiological analysis of liquid oral drugs available in Bangladesh. *Int. J. Pharm. Pharm. Sci.*, 5(4): 479-482.
- Kosmidis, C. et al. 2012. Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of *Staphylococcus aureus*. *Int. J. Antimicrob. Agents.*, 40, 204-209.
- Kumar, N. et al. 2014. Crystal structure of the transcriptional regulator Rv1219c of *Mycobacterium tuberculosis*. *Protein Sci.*, 23, 423-432.
- Lavigne, J. P. et al. 2013. An adaptive response of *Enterobacter aerogenes* to imipenem: regulation of porin balance in clinical isolates. *Int. J. Antimicrob. Agents.*, 41, 130-136
- Leclercq, R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. *Clin. Infect. Dis.*, 34, 482-492.

- Liu M., Van wyk B. E., Tinley P. M., 2003. A Taxonomic Evaluation of Fruit Structure in the Family Apiaceae, Ph. D thesis. University of Johannesburg, Auckland Park, South Africa.
- Livermore, D. M. 2008. Defining an extended-spectrum beta-lactamase. *Clin. Microbiol. Infect.* 14 (Suppl. 1), 3–10.
- Lynch, J. P., 3rd, Clark, N. M. and Zhanel, G. G. 2013. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β -lactamases and carbapenemases). *Expert Opin. Pharmacother.* 14, 199–210.
- Marioni J C., Mason C E., Mane S M., Stephens M. and Gilad Y. 2008. RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays, *Genome Res*, 18 1509.
- Mocroft A., Vella S., Benfield TL., Chiesi A., Miller V., Gargalianos P., d'Arminio Monforte A., Yust I., Bruun JN., Phillips AN., Lundgren JD. Euro SIDA Study Group. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1. *Lancet* 352:1725–1730. [http://dx.doi.org/10.1016/S0140-6736\(98\)03201-2](http://dx.doi.org/10.1016/S0140-6736(98)03201-2).
- Noor R., Akhter S., Rahman F., Munshi SK., Kamal SM., Feroz F. 2013. Frequency of extensively drug resistant tuberculosis(XDR-TB) among re-treatment cases in NIDCH, Dhaka, Bangladesh. *J Infect Chemother.*, 19(2): 243-248.
- Noor R., Hossain A., Munshi SK., Rahman F., Kamal SM. 2013. Slide drug susceptibility test for the detection of multi-drug resistant tuberculosis in Bangladesh. *J Infect Chemother.*, 19(5): 818-824.
- Noor R., Shaha SR., Rahman F., Munshi SK., Uddin MA., Rahman MM. 2012. Frequency of opportunistic and other intestinal parasitic infections in patients infected with human immunodeficiency virus in Bangladesh. *Tzu. Chi. Med. J.*, 24(4): 191-195.
- Nordmann, P., Poirel, L., Walsh, T. R. and Livermore, D. M. 2011. The emerging NDM carbapenemases. *Trends Microbiol.* 19, 588–595.
- Novais, *et al.* 2012. Spread of an OmpK36-modified ST15 *Klebsiella pneumoniae* variant during an outbreak involving multiple carbapenem-resistant Enterobacteriaceae species and clones. *Eur. J. Clin. Microbiol. Infect. Dis.* 31, 3057–3063.
- Ofokansi KC., Eze AO., Uzor PF. 2011. Evaluation of the antimicrobial activity of the aqueous and methanolic leaf extracts of *Mitacarpus villosus* with amoxicillin. *African Journal of Pharmacological Research* 3(1), 43-47.
- Olayinka Aiyegoro, Adekanmi Adewusi, Sunday Oyedemi, David Akinpelu, and Anthony Okoh 2011. Interactions of Antibiotics and Methanolic Crude Extracts of *Azelia Africana* (Smith.) Against Drug Resistance Bacterial Isolates *Int. J. Mol. Sci.*, 12, 4477-4487; doi: 10.3390/ijms12074477
- Olliver, A., Vallé, M., Chaslus-Dancla, E. and Cloeckaert, A. 2004. Role of an *acrR* mutation in multidrug resistance of in vitro-selected fluoroquinolone-resistant mutants of *Salmonella enterica* serovar Typhimurium. *FEMS Microbiol. Lett.* 238, 267–272.
- Paolo S. Ocampo, Viktria Ljzjr, Balz Papp, Markus Arnoldini, Pia Abel zur Wiesch, Rbert Busa-Fekete, Gergely Fekete, Csaba Pül, Martin Ackermann, Sebastian Bonhoeffer, 2014. Antagonism between Bacteriostatic and Bactericidal Antibiotics Is Prevalent. *Antimicrobial Agents and Chemotherapy* p. 4573–4582 Volume 58, Number 8.
- Papagiannitsis, C. C. *et al.* 2013. OmpK35 and OmpK36 porin variants associated with specific sequence types of *Klebsiella pneumoniae*. *J. Chemother.* 25, 250–254.
- Poirel, L., Bonnin, R. A. and Nordmann, P. 2012. Genetic support and diversity of acquired extended-spectrum β -lactamases in Gram-negative rods. *Infect. Genet. Evol.*, 12, 883–893.
- Poulou, A. *et al.* 2013. Outbreak caused by an ertapenem-resistant, CTX-M-15-producing *Klebsiella pneumoniae* sequence type 101 clone carrying an OmpK36 porin variant. *J. Clin. Microbiol.*, 51, 3176–3182.
- Pumbwe, L. and Piddock, L. J. V. 2000. Two efflux systems expressed simultaneously in multidrug-resistant *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 44, 2861–2864.
- Queenan, A. M. and Bush 2007. K. Carbapenemases: the versatile β -lactamases. *Clin. Microbiol. Rev.* 20, 440–458.
- Queenan, A. M., Shang, W., Flamm, R. and Bush, K (2010). Hydrolysis and inhibition profiles of β -lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. *Antimicrob. Agents Chemother.* 54, 565–569.
- Rana J., Sultana T., Das KK., Noor R. 2014. Microbiological analysis of topicals available in Bangladesh. *Int J Pharm Pharm Sci* 2014; 6(Suppl 2): 330- 332.
- Rao ML., Bhumi G., Savithamma N. 2013. Green synthesis of silver nanoparticles by *Allamanda cathartica* L. leaf extract and evaluation for antimicrobial activity. *Int. J. Pharm Sci Nanotech.*, 6(4).
- Rossolini, G. M., D'Andrea, M. M. and Mugnaioli, C. 2008. The spread of CTX-M-type extended-spectrum β -lactamases. *Clin. Microbiol. Infect.* 14 (Suppl. 1), 33–41.
- Sarker N., Islam S., Hasan M., Kabir F., Uddin MA., Noor R. 2013. Use of multiplex PCR assay for detection of diarrheagenic *Escherichia coli* in street vended food items. *Am J Life Sci.*, 1(6): 267-272.
- Schindler, B. D. *et al.* 2013. Functional consequences of substitution mutations in MepR, a repressor of the *Staphylococcus aureus* *mepA* multidrug efflux pump gene. *J. Bacteriol.* 195, 3651–3662.
- Sejal R., Priya N. 2012. Evaluation of antimicrobial activity of *Hibiscus rosa-sinensis*. *J. Pharm. Res.*, 5(6): 3318-3320.
- Selvamohan T., Ramadas V., Kishore SS. 2012. Antimicrobial activity of selected medicinal plants against some selected human pathogenic bacteria. *Adv. Appl. Sci. Res.*, 3(5): 3374-3381.
- Singh S., Gautam A., Sharma A., Batra A. 2010. *Centella Asiatica* (L.): A plant with immense medicinal potential But Threatened. *International Journal of Pharmaceutical Sciences Review and Research*, 4: 9-17.
- Tamber, S. and Hancock, R. E. 2003. On the mechanism of solute uptake in *Pseudomonas*. *Front. Biosci.*, 8, s472–s483
- Tamma, P.D., Cosgrove, S.E., Maragakis L.L. 2012. Combination therapy for treatment of infections with gram-negative bacteria, *Clin. Microbiol. Rev.*, 25, 450–470, <http://dx.doi.org/10.1128/CMR.05041-11>.
- Tangden, T., Adler, M., Cars, O., Sandegren, L. and Lowdin, E. 2013. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing *Escherichia coli* during exposure to ertapenem in an in vitro pharmacokinetic model. *J. Antimicrob. Chemother.* 68, 1319–1326.
- Tzouveleki, L. S., Markogiannakis, A., Psychogiou, M., Tassios, P. T. and Daikos, G. L. 2012. Carbapenemases in *Klebsiella pneumoniae* and other Enterobacteriaceae: an

- evolving crisis of global dimensions. *Clin. Microbiol. Rev.*, 25, 682–707.
- Urmi NJ., Noor R. 2014. Microbiological profile and the anti-bacterial traits of commonly available antacid suspensions in Dhaka metropolis. *Int. J. Pharm. Pharm. Sci.*, 6(4): 174–176.
- Van der Straaten, T., Janssen, R., Mevius, D. J. and van Dissel, J. T. 2004. Salmonella gene rma (ramA) and multiple-drug-resistant Salmonella enterica serovar typhimurium. *Antimicrob. Agents Chemother.* 48, 2292–2294.
- Van Iterson M., t'Hoen PAC., Pedotti P., Hooiveld G.J.E.J., den Dunnen J.T., van Ommen G.J.B., Boer J.M. and Menezes R X. 2009. Relative Power and sample size analysis on gene expression profiling data, *BMC Genomics*, 10 439 (e-pub).
- Vasu V T., Hobson B., Gohil K. and Cross C E. 2007. Genome-wide screening of alpha-tocopherol sensitive genes in heart tissue from alpha-tocopherol transfer protein null mice (ATTP(-/-)), *FEBS Lett*, 581 1572.
- Voulgari, E., Poulou, A., Koumaki, V. and Tsakris, A. 2013. Carbapenemase-producing Enterobacteriaceae: now that the storm is finally here, how will timely detection help us fight back? *Future Microbiol.* 8, 27–39.
- Wagner H. and Ulrich-Merzenich G. 2009. Synergy research: Approaching a new generation of phytopharmaceuticals Part I, *Phytomedicine*, 16/2-3 97.
- Warner, D. M., Shafer, W. M. and Jerse, A. E. 2008. Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC–MtrD–MtrE efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. *Mol. Microbiol.* 70, 462–478.
- Webber, M. A. and Piddock, L. J. V. 2001. Absence of mutations in marRAB or soxRS in acrB-overexpressing fluoroquinolone-resistant clinical and veterinary isolates of Escherichia coli. *Antimicrob. Agents Chemother.* 45, 1550–1552.
- WHO, 2010. WHO guidelines for the treatment of malaria, 2nd ed. WHO, Geneva, Switzerland.
- Woodford, N., Turton, J. F. and Livermore, D. M. 2011. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. *FEMS Microbiol. Rev.* 35, 736–755.
- Wozniak, R. A. and Waldor, M. K. 2010. Integrative and conjugative elements: mosaic mobile genetic elements enabling dynamic lateral gene flow. *Nature Rev. Microbiol.* 8, 552–563.
- Zhang, W. J. et al. 2014. Characterization of the IncA/C plasmid pSCEC2 from Escherichia coli of swine origin that harbours the multiresistance gene cfr. *J. Antimicrob. Chemother.* 69, 385–389.
- Zhao, W. H. and Hu, Z. Q 2013. Epidemiology and genetics of CTX-M extended-spectrum β -lactamases in Gram-negative bacteria. *Crit. Rev. Microbiol.* 39, 79–101.
